An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo

[1]  A. Rudensky,et al.  A nonimmune function of T cells in promoting lung tumor progression , 2017, The Journal of experimental medicine.

[2]  A. Kiyatkin,et al.  EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics , 2017, Cell.

[3]  A. Redig,et al.  Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2 , 2017, Nature Communications.

[4]  S. Fouzas,et al.  NRAS destines tumor cells to the lungs , 2017, EMBO molecular medicine.

[5]  D. Coppola,et al.  Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma , 2016, Molecular Cancer Therapeutics.

[6]  C. Lucchesi,et al.  Secretion of protein disulphide isomerase AGR2 confers tumorigenic properties , 2016, eLife.

[7]  J. Yokota,et al.  Gene aberrations for precision medicine against lung adenocarcinoma , 2016, Cancer science.

[8]  Haikuo Zhang,et al.  Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors , 2016 .

[9]  P. Lorenzo-Luaces,et al.  A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients , 2016, Clinical Cancer Research.

[10]  M. Meyerson,et al.  NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy , 2015, Molecular Cancer Therapeutics.

[11]  R. Prywes,et al.  Pathway Regulation of p63, a Director of Epithelial Cell Fate , 2015, Front. Endocrinol..

[12]  Jianqiang Mao,et al.  ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis , 2015, Cell reports.

[13]  Thomas D. Wu,et al.  A comprehensive transcriptional portrait of human cancer cell lines , 2014, Nature Biotechnology.

[14]  Elizabeth A. Calle,et al.  Repair and regeneration of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell function. , 2014, Cell stem cell.

[15]  Timothy R. Fallon,et al.  Yap tunes airway epithelial size and architecture by regulating the identity, maintenance, and self-renewal of stem cells. , 2014, Developmental cell.

[16]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[17]  William Pao,et al.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.

[18]  Angela N. Brooks,et al.  SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. , 2014, The Journal of clinical investigation.

[19]  Zhaoyuan Fang,et al.  Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma , 2014, Nature Communications.

[20]  Benjamin D. Medoff,et al.  Dedifferentiation of committed epithelial cells into stem cells in vivo , 2013, Nature.

[21]  Takeshi Nagayasu,et al.  Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung. , 2012, The Journal of clinical investigation.

[22]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[23]  U. Rapp,et al.  Conditional expression of oncogenic C-RAF in mouse pulmonary epithelial cells reveals differential tumorigenesis and induction of autophagy leading to tumor regression. , 2011, Neoplasia.

[24]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[25]  P. Jänne,et al.  Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. , 2010, Cancer research.

[26]  John R. Engen,et al.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.

[27]  Issa J. Dahabreh,et al.  Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC , 2009, Nature Reviews Clinical Oncology.

[28]  M. Meyerson,et al.  HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy , 2009, Proceedings of the National Academy of Sciences.

[29]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[30]  Jie Zhang,et al.  Intratumoral Epiregulin Is a Marker of Advanced Disease in Non–Small Cell Lung Cancer Patients and Confers Invasive Properties on EGFR-Mutant Cells , 2008, Cancer Prevention Research.

[31]  John D. Minna,et al.  Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops , 2008, Cancer Prevention Research.

[32]  Jiandie D. Lin,et al.  TEAD mediates YAP-dependent gene induction and growth control. , 2008, Genes & development.

[33]  A. R. Thitoff,et al.  Conditional deletion of Pten causes bronchiolar hyperplasia. , 2008, American journal of respiratory cell and molecular biology.

[34]  T. Mak,et al.  Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. , 2007, The Journal of clinical investigation.

[35]  R. Schmid,et al.  Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. , 2007, Cancer cell.

[36]  W. Pao,et al.  Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors , 2007, PloS one.

[37]  D. Neil Hayes,et al.  LKB1 modulates lung cancer differentiation and metastasis , 2007, Nature.

[38]  M. Meyerson,et al.  Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. , 2007, Cancer cell.

[39]  Levi A Garraway,et al.  Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. , 2007, Cancer research.

[40]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[41]  H. Varmus,et al.  Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. , 2006, Genes & development.

[42]  J. Whitsett,et al.  PARP-2 Interacts with TTF-1 and Regulates Expression of Surfactant Protein-B* , 2006, Journal of Biological Chemistry.

[43]  R. Wanke,et al.  Betacellulin overexpression in transgenic mice causes disproportionate growth, pulmonary hemorrhage syndrome, and complex eye pathology. , 2005, Endocrinology.

[44]  William C Hahn,et al.  Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants , 2005, PLoS medicine.

[45]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.

[46]  M. Yaffe,et al.  TAZ Interacts with TTF-1 and Regulates Expression of Surfactant Protein-C* , 2004, Journal of Biological Chemistry.

[47]  J. Tichelaar,et al.  Conditional expression of transforming growth factor-alpha in adult mouse lung causes pulmonary fibrosis. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[48]  H. Varmus,et al.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. , 2001, Genes & development.

[49]  R. Schmid,et al.  Malignant transformation of duct-like cells originating from acini in transforming growth factor transgenic mice. , 1998, Gastroenterology.

[50]  E. Dmitrovsky,et al.  Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  J. Whitsett,et al.  Respiratory epithelial cell expression of human transforming growth factor-alpha induces lung fibrosis in transgenic mice. , 1994, The Journal of clinical investigation.

[52]  K. Sugimachi,et al.  Prognostic implication of transforming growth factor alpha in adenocarcinoma of the lung--an immunohistochemical study. , 1991, British Journal of Cancer.

[53]  R. Palmiter,et al.  Overexpression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast , 1990, Cell.

[54]  G. Merlino,et al.  TGFα overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas , 1990, Cell.

[55]  I. Pastan,et al.  Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. , 1987, Science.

[56]  A. McCullough.  Comprehensive genomic characterization of squamous cell lung cancers , 2013 .

[57]  J. Whitsett,et al.  Conditional expression of genes in the respiratory epithelium in transgenic mice: cautionary notes and toward building a better mouse trap. , 2009, American journal of respiratory cell and molecular biology.